US3917582A - Isothiocyanate and thiourea derivatives of benzoyl ecgonine conjugated to polypeptides - Google Patents
Isothiocyanate and thiourea derivatives of benzoyl ecgonine conjugated to polypeptides Download PDFInfo
- Publication number
- US3917582A US3917582A US369658A US36965873A US3917582A US 3917582 A US3917582 A US 3917582A US 369658 A US369658 A US 369658A US 36965873 A US36965873 A US 36965873A US 3917582 A US3917582 A US 3917582A
- Authority
- US
- United States
- Prior art keywords
- ecgonine
- benzoyl ecgonine
- conjugated
- isothiocyanate
- usually
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 title abstract description 38
- 229920001184 polypeptide Polymers 0.000 title abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 22
- 150000002540 isothiocyanates Chemical class 0.000 title abstract description 10
- 150000003585 thioureas Chemical class 0.000 title description 2
- 230000000890 antigenic effect Effects 0.000 claims abstract description 22
- -1 POLY(AMINO ACID) Polymers 0.000 claims description 35
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical class O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 abstract description 42
- 102000004190 Enzymes Human genes 0.000 abstract description 31
- 108090000790 Enzymes Proteins 0.000 abstract description 31
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract description 17
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 238000003018 immunoassay Methods 0.000 abstract description 14
- 230000021615 conjugation Effects 0.000 abstract description 11
- 229960003920 cocaine Drugs 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 5
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108010014251 Muramidase Proteins 0.000 description 6
- 102000016943 Muramidase Human genes 0.000 description 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960000274 lysozyme Drugs 0.000 description 6
- 239000004325 lysozyme Substances 0.000 description 6
- 235000010335 lysozyme Nutrition 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical class NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 4
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 4
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 231100000319 bleeding Toxicity 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- QIQNNBXHAYSQRY-UYXSQOIJSA-N ecgonine methyl ester Chemical compound C1[C@H](O)[C@H](C(=O)OC)[C@H]2CC[C@@H]1N2C QIQNNBXHAYSQRY-UYXSQOIJSA-N 0.000 description 2
- QIQNNBXHAYSQRY-UHFFFAOYSA-N ecgonine methyl ester Natural products C1C(O)C(C(=O)OC)C2CCC1N2C QIQNNBXHAYSQRY-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HVWQTEPEBQYIFB-PXXJPSRFSA-N (1s,3s,4r,5r)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylic acid;hydrochloride Chemical compound [Cl-].C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1[NH+]2C HVWQTEPEBQYIFB-PXXJPSRFSA-N 0.000 description 1
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000283960 Leporidae Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 101710157833 Lysozyme A Proteins 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 244000128833 Mimulus luteus Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940003587 aquaphor Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- RLLMNWXOZDXKCQ-NPPHLGRCSA-N hydron;methyl (1s,3s,4r,5r)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate;chloride Chemical compound Cl.C1[C@H](O)[C@H](C(=O)OC)[C@H]2CC[C@@H]1N2C RLLMNWXOZDXKCQ-NPPHLGRCSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 108010001073 oxyhemoglobin oxidase Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/822—Identified hapten
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
Definitions
- ABSTRACT Novel benzoyl ecgonine derivatives having an isothiocyanate group for conjugation to polypeptides and proteins to provide derivatives as reagents in immunoassays or for preparation of reagents for immunoassays.
- the isothiocyanate is conjugated to enzymes or antigenic polypeptides or proteins.
- the antigenic polypeptides or proteins are employed for preparing antibodies to benzoyl ecgonine or cocaine, while the conjugated enzymes are used in immunoassays, where the enzyme is the detector molecule.
- the enzyme conjugate is found to have a high degree of sensitivity for the detection of henzoyl ecgonine, a cocaine metabolite.
- the compounds of this invention are thiocarbamoyl derivatives of benzoyl ecgonine or its methyl ester, as well as the antibodies prepared from the antigenic conjugates of the benzoyl ecgonine derivative with an antigenic poly(amino acid).
- n is the number of benzoyl ecgonine groups conjugated to the poly(amino acid) and on the average will be at least 1 and not :more than the molecular weight of B divided by 500, more usually not more than the molecular weight of B divided by 2000,
- the thiocarbamoyl group may be meta or para, usu ally para.
- R is hydrogen or methyl, usually hydrogen, and the isothiocyanate group is either meta or para, normally para.
- the isothiocyanate compound is prepared by esterifying the appropriate ecgonine derivative with the appropriate nitrobenzoic acid. The ester may then be reduced to the aminobenzoate, conveniently employing catalytic hydrogenation. The amino compound may then be derivatized to the isothiocyanate using thiophosgene. The amino compound is combined with the thiophosgene under mild conditions.
- Conjugation of the isothiocyanate to a poly(amino acid) is carried out by combining the appropriate ratio of the isothiocyanate to the poly(amino acid) under mild conditions and at a constant mildly basic pH, normally in the range of about 8 to 9.
- poly(amino acid) is intended both polypeptides and proteins.
- One group of poly(amino acids) is antigenic, so that by conjugation of the isothiocyanate to the antigenic poly(amino acid) a product is obtained which can be used in the formation of antibodies to benzoyl ecgonine.
- a narrow class of poly(amino acids), which can also be used as antigens, though not normally be used as such, are enzymes which are employed as the detector in an immunoassay system.
- Polypeptides usually encompass from about 2 to 100 amino acid units (usually less than about 12,000 molecular weight). Larger polypeptides are arbitrarily called proteins. Proteins are usually composed of from 1 to 20 polypeptide chains, called subunits, which are associated by covalent or non-covalent bonds. Subunits are normally of from 100 to 300 amino acid groups (approximately 10,000 to 35,000 molecular weight). For the purposes of this invention, polypeptide is intended to include individual polypeptide units or polypeptides which are subunits of proteins, whether composed solely of polypeptide units or polypeptide units in combination with other functional groups, such as porphyrins, as in hemoglobin or cytochrome oxidase.
- the first group of poly(amino acid) materials which will be considered are the antigenic poly(amino acids). These may be joined to the isothiocyanate group through an amino group.
- the thiourea product which may include some thiourethane, can be used for the formation of antibodies to cocaine metabolites.
- the poly(amino acid) materials which may be used vary widely, normally being from about 1,000 to million molecular weight, more usually from 12,000 to 1 million molecular weight, and most frequently from about 50,000 to 500,000 molecular weight.
- the number of benzoyl ecgonine or derivative groups will be in the range of l to 10, usually in the range of 2 to 5. Therefore, there may be as many as one benzoyl ecgonine or derivative group per 500 molecular weight of poly(amino acid).
- the number of groups bonded to the poly(amino acid) will be related to the available amino groups, e.g., the number of lysines present. While the benzoyl ecgonine or derivative group may be bonded through the isothiocyanate to hydroxyl or mercaptan groups, which are present in the polypeptide, for the most part the bonding will be to amino and, therefore, the compounds are described as thioureas. However, thionoesters may also be present.
- Amino acids present in poly(.amino acids) which have free amino groups for bonding to the isothiocyanate modified benzoyl ecgonine or derivative thereof, include lysine, arginine, histidine, etc.
- the hydroxylated and mercpatan substituted amino acids include serine, cystene and threonine.
- proteins may be employed as the antigenic material. These types include albumin, serum proteins, e.g., globulins, ocular lens proteins, lipoproteins, etc. Illustrative proteins include bovine 'y-globulin, etc. Small natural polypeptides which are immunogenic, such as gramicidin may also be employed. Various synthetic polypeptides may also be employed, such as polymers of lysine, glutamic acid, phenylalanine, tyrosine, etc., either by themselves or in combination. Of particular interest is polylysine or a combination of lysine and glutamic acid. Any synthetic polypeptide must contain a sufficient number of active groups, as for example, amino groups provided by lysine.
- the second group of poly(amino acids) are the enzymes to which the isothiocyanate derivative may be conjugated.
- the benzoyl ecgonine derivative modified enzyme is useful for immunoassays. The immunoassay technique will follow in more detail.
- oxidoreductases such as oxidoreductases, hydrolases, lyases, and the like. These enzymes include esterases, amidases, phosphorylases, carbohydrases, oxidases, reductases and the like. Of particular interest are such enzymes as lysozyme, amylase, dehydrogenases, particularly malate dehydrogenase, lactate dehydrogenase, mannitol-l-phosphate dehydrogenase, and glucose 6-phosphate dehydrogenasee, B-glucuronidase, cellulase, and phospho-lipas e, particularly phospholipase C.
- the enzymes will usually have molecular weights in the range of about 1 X 10 to 6 X 10 more usually in the range of about 1.2 X 10 to 3 X 10 There will usually be at least one benzoyl ecgonine or derivative group per enzyme molecule and usually not more than one group per 1,500 molecular weight, usually not more than one group for 2,000 molecular weight. Usually, there will be at least one benzoyl ecgonine or derivative group per 50,000 molecular weight, and more usually at least one group per 30,000 molecular weight.
- the modified enzyme will retain on the average at least 10%, more usually at least 30% of the original activity of the unmodified enzyme.
- the benzoyl ecgonine or derivative is bonded to a poly(amino acid), there need be only one benzoyl ecgonine or derivative group, but usually there will be at least two groups.
- the number of benzoyl ecgonine or derivative groups will generally be of from I to 30, more usually 2 to 25. Usually, there will be at least two, more usually at least three groups per enzyme, when the enzyme is randomly substituted with the benzoyl ecgonine or derivative groups, and preferably not more than 16 groups.
- the substituted poly(amino acid)s will, for the most part, have the following formula:
- the molecules bonded to the isothiocyanate will normally be of from 8 to 16 carbon atoms, usually of from 8 to 12 carbon atoms.
- the functionality for linking to the ecgonine derivative may be bonded directly to an annular carbon atom or bonded to an annular carbon atom through an aliphatic chain of from 1 to 4 carbon atoms, usually of from 1 to 2 carbon atoms.
- the molecules may have from O to 2 sites of ethylenic unsaturation, more usually from 0 to 1 site of ethylenic unsaturation.
- X is a divalent aliphatic radical, having from 0 to l site'of aliphatic unsaturation, usually aliphatically saturated of from 1 to 6 carbon atoms, usually from 2 to 3 carbon atoms being annular atoms;
- A is lower alkyl (1 to 6, usually one to 3 carbon atoms), preferably methyl
- Y is of the following formula:
- a hapten is conjugated to an antigenic material such as a polypeptide or protein, although polysaccharides, particularly containing aminosugars, can also be used.
- the particular manner in which the hapten is bonded to the antigenic material will depend on the functionalities which are available on the haptenic material and the antigenic material, the number of haptenic groups to be conjugated to the antigenic material, and the like.
- Groups which find use include carboxy groups, which may be activated by employing the mixed carbonic acid anhydride or carbodiimide, imidates, diazo groups, ahaloketones, and the like. Numerous procedures for the conjugation of a wide variety of haptens have been developed and published.
- the antigenic conjugate may be injected in the fluid state; adsorbed to insoluble particles, such as alumina; or incorporated in matrix materials such as agar, calcium alginate, or Freunds adljuvants (complete or incomplete, depending on whether mycobacteria are incorporated).
- insoluble particles such as alumina
- matrix materials such as agar, calcium alginate, or Freunds adljuvants (complete or incomplete, depending on whether mycobacteria are incorporated).
- the adsorbtion to various insoluble colloidal carriers is described in the aforementioned text, the carriers being illustrated by alumina, aluminum phosphate, blood charcoal and the like. Other materials include polyacrylamide gel, bentonite, and protein.
- As adjuvants, methylated bovine serum albumin and Freunds adjuvant find use.
- Complete Freunds adjuvant is a water-in-oil emulsion, using emulsion stabilizers such as lanolin, lanolin derivatives, e.g., Aquaphor, mannide mono-oleate and Arlacel A, available from Duke Laboratories, South Newark, Connecticut.
- the complete adjuvant is distinguished from the incomplete adjuvant by having mycobacteria, e.g., M.butyricum or M.tuberculo sis.
- the adjuvants are commercially available from Difco Laboratories, Detroit, Michigan.
- Immunization can be carried out in a variety of ways with a number of different animals.
- relatively large animals such as equine, bovine, porcine, canine, ovine, caprine, rodentia, rabbits and hares.
- horses, goats, sheep and cows Of particular interest are horses, goats, sheep and cows, that is, the larger domestic animals, as well as rabbits.
- the antigenic material mayv be injected interperitoneally, intramuscularly, subcutaneously, and the like.
- the amount of antigen employed will vary depending on the particular antigenic material and the number and period of prior injections. Usually, about 0.1 to 5 mg of antigenic material will be employed per one ml of solution. The total amount of antigenic material and solution will depend on the size, nature and weight of the animal employed. The initial injection will normally be at a number of sites, aliquots of the composition being employed.
- the first injections of antigen serve to load the animal, and a period of time is allowed to pass before booster injections are introduced, normally 2 to 8 weeks. Bleeding may occur after each injection, so as to follow the formation of the desired antibody. Depending on the animal, bleedings can be carried out via heart puncture, the carotid artery or external jugular 7 with calcium chloride, with clotting resulting. 1f necessary, thrombin may be added to enhance clotting. After breaking up the clot, the clot is compressed and serum is withdrawn and filtered. Various other procedures are known and can be employed. 1
- the serum can be treated in various ways, depending on its subsequent use.
- the serum may be fractionated by employing ethanol, Rivanol, neutral salts, such as ammonium sulfate or sodium sulfate, or the like.
- the product will be dialyzed after dissolution in a buffer, filtered and then isolated.
- the serum may be chromatographed on various modified cellulose columns, e.g., diethylaminoethylcellulose or carboxymethylcellulose.
- modified cellulose columns e.g., diethylaminoethylcellulose or carboxymethylcellulose.
- Various physical means may be employed to concentrate the desired antibodies.
- the antibodies are primarily 'y-globulin which are found to have a molecular weight of about 150,000.
- the antibodies will be specific for a particular spatial structure and polar-non-polar distribution. Varying structures deviating from an ideal structure will give different binding constants.
- EXAMPLE 1 Preparation of para-Aminobenzoylecgonine A.
- Ecgonine hydrochloride (5.5g, 24.8 mmoles) was dissolved in 35ml of methanol (dried over 3-A Molecular sieves) and saturated with dry hydrogen chloride keeping the receiver cool by immersion in an ice bath. Upon saturation the receiver was heated to 40 for 0.5 hour and evaporated to dryness in vacuo. The white residue was stored at 0.05mm Hg over potassium hydroxide for 16 hours and then dissolved in the minimum amount of hot methanol to which 200ml of boiling acetone was quickly added. After cooling in ice and filtering, there was obtained 4.2g of white crystals, m.p. 214-2l5 (lit. 2l42l5). Evaporation of the motherliquor and repetition of the recrystallization yielded 0.8g m.p. 2l2-214. Total yield was 86.3% of theory.
- the resulting dialysate was assayed for enzyme activity in the presence of NAD and glucose-6-phosphate by measuring the increase in absorption at 340nm. That benzoyl ecgonine had been attached to the enzyme was shown by the change in enzyme activity in the presence and absence of benzoyl ecgonine antibodies.
- Enzyme Rate Amount of Benzoyl Ecgonine The addition of 50p.l of antibody results in a 34% inhibition of enzyme activity.
- the following reagents are employed: 0.1M NAD in H O, pH adjusted to 5-6 with 0.05M NaOl-l; 0.066M glucose-6-phosphate (G-6-P) in 0.055M .Tris-Cl, pH 7.9; 0.055M Tris-Cl buffer, pH 7.9 with 0.1% rabbit serum albumin.
- a spectrophotometer cell Into a spectrophotometer cell is metered 1.1 NAD, 5011.1 G-6-P, specified amount of antibody solution, 10111 of a 1:4 dilution of the enzyme dialysate and sufficient buffer to bring the total volume to lml.
- the optical density is read at 340nm for 5 minutes and the enzyme rate determined by averaging the rate between the second and fifth minute.
- the temperature is maintained at 37.
- the immunoassay employing an enzyme as the detector is carried out as follows. With lysozyme, a bacterial suspension of M.luteus is employed, dissolving 0.2m] of a suspension of 300mg of the bacteria in 400ml of 0.025M, pH6,Tris-maleate buffer. First the bacterial suspension is introduced into the assay vessel. When testing a sample, 50p] of the sample is then introduced. This is followed by 5011.1 of antibody solution in 0.025M, pl-I6, Tris-maleate buffer and the transfer made quantitative by washing with 325 11 of the same buffer solution.
- the benzoyl ecgonine conjugate to lysozyme (50 .tl) is then added to give a binding site to 10 benzoyl ecgonine ratio of about 121.5 and 325 1.1 of buffer used to insure quantative transfer.
- the results are then read by observing the decrease in optical density at 436nm for 40 seconds at 36.
- the results are reported in OD/mirt.
- the antibody employed was obtained in response to a conjugate of para-diazabenzoyl ecgonine with bovine serum albumin.
- the binding constant was about 1 X 10 M.
- the concentration of antibody was 6.9 X 10' m, based on binding sites as determined employing a free radical assay technique with a cocaine spin label.
- Methamphetamine Employing the benzoyl ecgonine conjugate to lysozyme in accordance with the previously described method, the assay was found to have excellent sensitivity and reproducibility of results in the range of 0.5 to 5 pg per ml concentration of benzoyl ecgonine.
- Ten urine samples were each spiked to levels of 1 pg per ml and 5 .Lg per ml of benzoyl ecgonine. Each sample was assayed in triplicate and the average value of each sample was used to calculate the experimental concentration and the percent recovery. The recovery observed contained some contribution of spiking error, operator error, and the urine variation. The average recovery of activity lies around The following tables indicate the results.
- the lysozyme benzoyl ecgonine conjugate employed in the subject assay is found to be stable for long periods of time when stored at 4C.
- the enzyme retains a substantial proportion of the original activity after conjugation, so as to provide a high degree of activity in the assay.
- the enzyme conjugate is able to provide a substantial rate change when the amount of benzoyl ecgonine is varied from 0.5 to 5.0 ug/ml. Therefore, the subject conjugate provides an accurate, effective and rapid method for determining extremely small quantities of benzoyl ecgonine.
- the assay only requires 50ul or less of urine sample, so that extremely small amounts of benzoyl ecgonine are required for detection.
- R is hydrogen or methyl
- PP is an antigenic poly(amino acid) of at least 1000 molecular weight bonded through amino groups to form a thiourea
- n is the number of groups bonded to the poly(amino acid), and in the range of about one to the molecular weight of the poly(amino acid) divided by 1000.
- R is hydrogen
- n is in the range of 1 to 200
- PP has a molecular weight in the range of 12,000 to 1 million.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US369658A US3917582A (en) | 1973-06-13 | 1973-06-13 | Isothiocyanate and thiourea derivatives of benzoyl ecgonine conjugated to polypeptides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US369658A US3917582A (en) | 1973-06-13 | 1973-06-13 | Isothiocyanate and thiourea derivatives of benzoyl ecgonine conjugated to polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3917582A true US3917582A (en) | 1975-11-04 |
Family
ID=23456366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US369658A Expired - Lifetime US3917582A (en) | 1973-06-13 | 1973-06-13 | Isothiocyanate and thiourea derivatives of benzoyl ecgonine conjugated to polypeptides |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3917582A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4071522A (en) * | 1977-01-06 | 1978-01-31 | Hoffmann-La Roche Inc. | Tritiated O-benzoylecgonine |
| US4102979A (en) * | 1976-09-22 | 1978-07-25 | Hoffmann-La Roche Inc. | Radioimmunoassay for benzoylecgonine |
| US4123431A (en) * | 1973-05-29 | 1978-10-31 | Syva Company | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds and derivatives thereof |
| US4207307A (en) * | 1977-01-21 | 1980-06-10 | Research Corporation | Simultaneous immunoassay of multiple antigens and assay for cocaine metabolites |
| US4235864A (en) * | 1978-04-10 | 1980-11-25 | Research Corporation | Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites |
| US4378428A (en) * | 1981-03-30 | 1983-03-29 | Baker Instruments Corporation | Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays |
| WO1987006594A1 (en) * | 1986-04-30 | 1987-11-05 | Southwest Foundation For Biomedical Research | Polyamide resin and method for preparation of reagents for immunodiagnostic use |
| US4785080A (en) * | 1981-03-30 | 1988-11-15 | Baker Instruments Corporation | Labeled analytes |
| WO1993003367A1 (en) * | 1991-07-29 | 1993-02-18 | Serex, Inc. | Differential binding affinities and dissociation assays based thereon |
| US5202270A (en) * | 1986-05-15 | 1993-04-13 | Abbott Laboratories | Cocaine and cocaine metabolites assay tracers, immunogens and antibodies |
| WO1993012111A1 (en) * | 1991-12-16 | 1993-06-24 | Biosite Diagnostics Incorporated | Novel cocaine derivatives and protein and polypeptide cocaine derivative conjugates and labels |
| WO1993020076A1 (en) * | 1992-04-03 | 1993-10-14 | The Trustees Of Columbia University In The City Of New York | Catalytic antibodies against cocaine and methods of using and producing same |
| US5618926A (en) * | 1989-03-10 | 1997-04-08 | Hoffmann-La Roche Inc. | Immunoassay reagents |
| US5808074A (en) * | 1996-02-02 | 1998-09-15 | Georgetown University | Benzoylecgonine conjugate diagnostic reagents |
| US5948658A (en) * | 1996-06-25 | 1999-09-07 | The Trustees Of Columbia University In The City Of New York | Anti-cocaine catalytic antibody |
| US6114508A (en) * | 1997-03-21 | 2000-09-05 | Drugabuse Sciences, Inc. | Cocaethylene immunogens and antibodies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3690834A (en) * | 1971-01-11 | 1972-09-12 | Syva Co | Ligand determination with spin labeled compounds by receptor displacement |
-
1973
- 1973-06-13 US US369658A patent/US3917582A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3690834A (en) * | 1971-01-11 | 1972-09-12 | Syva Co | Ligand determination with spin labeled compounds by receptor displacement |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4123431A (en) * | 1973-05-29 | 1978-10-31 | Syva Company | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds and derivatives thereof |
| US4102979A (en) * | 1976-09-22 | 1978-07-25 | Hoffmann-La Roche Inc. | Radioimmunoassay for benzoylecgonine |
| US4071522A (en) * | 1977-01-06 | 1978-01-31 | Hoffmann-La Roche Inc. | Tritiated O-benzoylecgonine |
| US4207307A (en) * | 1977-01-21 | 1980-06-10 | Research Corporation | Simultaneous immunoassay of multiple antigens and assay for cocaine metabolites |
| US4235864A (en) * | 1978-04-10 | 1980-11-25 | Research Corporation | Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites |
| US4378428A (en) * | 1981-03-30 | 1983-03-29 | Baker Instruments Corporation | Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays |
| US4785080A (en) * | 1981-03-30 | 1988-11-15 | Baker Instruments Corporation | Labeled analytes |
| WO1987006594A1 (en) * | 1986-04-30 | 1987-11-05 | Southwest Foundation For Biomedical Research | Polyamide resin and method for preparation of reagents for immunodiagnostic use |
| US5202270A (en) * | 1986-05-15 | 1993-04-13 | Abbott Laboratories | Cocaine and cocaine metabolites assay tracers, immunogens and antibodies |
| US5618926A (en) * | 1989-03-10 | 1997-04-08 | Hoffmann-La Roche Inc. | Immunoassay reagents |
| WO1993003367A1 (en) * | 1991-07-29 | 1993-02-18 | Serex, Inc. | Differential binding affinities and dissociation assays based thereon |
| WO1993012111A1 (en) * | 1991-12-16 | 1993-06-24 | Biosite Diagnostics Incorporated | Novel cocaine derivatives and protein and polypeptide cocaine derivative conjugates and labels |
| WO1993020076A1 (en) * | 1992-04-03 | 1993-10-14 | The Trustees Of Columbia University In The City Of New York | Catalytic antibodies against cocaine and methods of using and producing same |
| US5977314A (en) * | 1992-04-03 | 1999-11-02 | The Trustees Of Columbia University In The City Of New York | Catalytic antibodies against cocaine |
| US5990285A (en) * | 1992-04-03 | 1999-11-23 | The Trustees Of Columbia University | Catalytic antibodies against cocaine |
| US6184013B1 (en) | 1992-04-03 | 2001-02-06 | The Trustees Of Columbia University In The City Of New York | Catalytic antibodies against cocaine and methods of using and producing same |
| US5808074A (en) * | 1996-02-02 | 1998-09-15 | Georgetown University | Benzoylecgonine conjugate diagnostic reagents |
| US5948658A (en) * | 1996-06-25 | 1999-09-07 | The Trustees Of Columbia University In The City Of New York | Anti-cocaine catalytic antibody |
| US6280987B1 (en) | 1996-06-25 | 2001-08-28 | The Trustees Of Columbia University In The City Of New York | Anti-cocaine catalytic antibody |
| US6913917B2 (en) | 1996-06-25 | 2005-07-05 | The Trustees Of Columbia University In The City Of New York | Anti-cocaine catalytic antibody |
| US6114508A (en) * | 1997-03-21 | 2000-09-05 | Drugabuse Sciences, Inc. | Cocaethylene immunogens and antibodies |
| US6541004B1 (en) | 1997-03-21 | 2003-04-01 | Drugabuse Sciences, Inc. | Cocaethylene immunogens and antibodies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3917582A (en) | Isothiocyanate and thiourea derivatives of benzoyl ecgonine conjugated to polypeptides | |
| US4123431A (en) | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds and derivatives thereof | |
| US3843696A (en) | Methadone analog compounds | |
| US3888866A (en) | Nitrogen derivatives of benzoyl ecgonine | |
| US4197237A (en) | Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof | |
| US4043872A (en) | Polyiodothyronine immunoassay | |
| US3884898A (en) | Normorphine derivatives bonded to proteins | |
| US4399121A (en) | Iodothyronine immunogens and antibodies | |
| US4302438A (en) | Antigen, antiserum and immunoassay for theophylline | |
| US3867366A (en) | Opiate imidates and protein conjugates thereof | |
| US4040907A (en) | Iodothyronine enzyme conjugates | |
| US4190496A (en) | Homogeneous enzyme assay for antibodies | |
| US4025501A (en) | Polypeptide propoxyphene derivatives for immunoassay reagents | |
| US4171244A (en) | Enzyme-bound-polyidothyronine | |
| US4058511A (en) | Tegretol antigens and antibodies | |
| US3704282A (en) | Catecholamine antigens and antibodies specific therefor | |
| US4281065A (en) | Phencyclidine conjugates to antigenic proteins and enzymes | |
| Fuchs et al. | Immunological studies of plant hormones: detection and estimation by immunological assays | |
| US3975237A (en) | Compounds for enzyme amplification assay - - ecgonine analogs | |
| CA1212057A (en) | Acetaminophen analogs, antigens and antibodies | |
| US3976763A (en) | Chlorpromazine assay | |
| US9777069B2 (en) | Compositions and methods for detection of methadone metabolite | |
| US4235969A (en) | Procainamide antigen conjugates and antibodies | |
| US10351830B2 (en) | Conjugates for assays for oxycodone and oxymorphone | |
| US4243654A (en) | Oxazepam derivatives for immunoassay reagents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: DEUTSCHE BANK AG, NEW YORK Free format text: ;ASSIGNOR:DADE MICROSCAN INC.;REEL/FRAME:013516/0250 Effective date: 20021001 Owner name: DEUTSCHE BANK AG, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:DADE MICROSCAN INC.;REEL/FRAME:013599/0629 Effective date: 20021003 |
|
| AS | Assignment |
Owner name: DEUTSCHE BANK AG, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:SYVA COMPANY;REEL/FRAME:013542/0411 Effective date: 20021001 |
|
| AS | Assignment |
Owner name: DADE MICROSCAN INC., ILLINOIS Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK AG, NEW YORK BRANCH;REEL/FRAME:015953/0315 Effective date: 20050426 Owner name: SYVA COMPANY, ILLINOIS Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK AG, NEW YORK BRANCH;REEL/FRAME:015953/0326 Effective date: 20050426 |